Kamada (NASDAQ:KMDA) is a biopharmaceutical company that focuses on the development, production and commercialization of plasma-derived and recombinant protein therapeutics for the treatment of rare and serious diseases. Headquartered in Rehovot, Israel, the company operates a fully integrated manufacturing facility that spans plasmaderived fractionation, purification, fill/finish and quality control. Kamada’s business model centers on leveraging proprietary purification processes and recombinant protein technologies to deliver therapies with enhanced safety profiles and consistent supply.
The company’s marketed products include Alpha-1 Proteinase Inhibitor (Glassia), indicated for patients with alpha-1 antitrypsin deficiency, and human rabies immunoglobulin (KEDRAB) for post‐exposure prophylaxis of rabies. Kamada has established distribution partnerships in the United States, Europe and other international markets to support the global reach of its commercial portfolio. In addition to finished product supply, the company offers dedicated contract development and manufacturing services (CDMO) for plasmaderived and recombinant proteins.
Alongside its approved therapies, Kamada maintains a clinical pipeline targeting pulmonary and inflammatory disorders. Key investigational programs include AAT for the treatment of rare lung diseases and CMP-001, an immuno‐oncology compound undergoing clinical evaluation. These development efforts are aimed at expanding the company’s footprint in orphan indications where high unmet medical need exists.
Founded in 1990, Kamada has grown from a local start‐up into a Nasdaq‐listed enterprise with operations spanning Israel, North America and Europe. The company’s leadership team combines scientific expertise and commercial experience, guiding Kamada’s strategic collaborations, regulatory activities and market expansion initiatives. Through its integrated platform and focus on specialty proteins, Kamada seeks to deliver long‐term value to patients and stakeholders worldwide.
